Abstract 97P
Background
Myocarditis is a rare adverse effect of immune-checkpoint inhibitor therapy (ICI) associated with a high fatality rate and no clear predeterminants. European Society of Cardiology suggests baseline cardiac assessment and serial monitoring with ICI treatment. The volume of investigations recommended has been a barrier to adoption in practice.
Methods
We conducted a prospective study of clinical utility of baseline and serial cardiac assessment in a UK tertiary hospital. Patients were risk stratified by cardiac history, risk factors, baseline bloods including cardiac biomarkers and cardiac investigations, repeated at 3-4 weeks and 6-8 weeks. Aims; test feasibility; assess the value in risk stratifying patients to predict risk; determine if serial monitoring identified early cardiac toxicity.
Results
175 patients, 86 High risk, 89 Low risk. 8/175 patients baseline troponin >30. 28/175 patients baseline BNP >400. 2 patients had a troponin rise at 3-4 week, neither developed cardiotoxicity. 7 developed a troponin rise at 6-8 weeks, none developed cardiotoxicity. 32 patients had a BNP rise at 3-4 weeks. 9 significant. 1 patient BNP increased to >1000 without cardiotoxicity. 5 patients BNP approximately doubled; 2 patients rose >1000, 1 without cardiotoxicity, 1 who developed myocarditis later. 2 symptomatic patients with raised biomarkers and were treated for cardiotoxicity. 1 presented in SVT, LVEF 33%, CMR negative for myocarditis. 1 with syncopal episodes. In both cases biomarkers reduced on steroids, ICI was terminated.
Conclusions
All patients who developed cardiotoxicity were screened as high risk. 2 patients with cardiotoxicity were identified through clinical assessment not serial monitoring. Interpretation of cardiac biomarkers should accompany careful clinical assessment and liaison with cardiology. Baseline assessment supports decision making. Risk stratification may be a way to streamline monitoring.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract